Mezagitamab produced clinically meaningful platelet count increases in a Phase 2 trial for immune thrombocytopenia, according to the reported findings. The antibody approach targets the underlying autoimmune drivers of ITP by modulating platelet destruction and/or immune effects that reduce platelet availability. The trial results are positioned as a potential step toward more effective and durable therapies in ITP, where treatment often requires balancing bleeding risk against immune and tolerability considerations. For developers, successful Phase 2 readouts can also improve the design of confirmatory studies by clarifying response patterns. The company’s next steps will likely focus on durability, subgroup response consistency, and safety profiling to determine how the therapy could fit into existing ITP treatment algorithms.